[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575777":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"IRCCS Sacro Cuore Don Calabria di Negrar","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients",null,"All pediatric and adult subjects attending the travel clinic of the DITM for the administration of Dengue vaccine.",[13],"Drug: Qdenga",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Qdenga","Administration of Dengue vaccine and blood sample collection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Elvia Malo","CONTACT","+390456013111","elvia.malo@sacrocuore.it",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"IRCCS Sacro Cuore Don Calabria","RECRUITING","Negrar","VR","37024","Italy","IT",{"type":36,"coordinates":37},"Point",[38,39],10.93899,45.52918,{"lat":39,"lon":38},[42,46],{"name":43,"role":23,"phone":10,"phoneExt":44,"email":45},"Concetta Castilletti","+396013111","concetta.castilletti@sacrocuore.it",{"name":43,"role":47,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100575777","characterisation-of-dengue-vaccine-induced-specific-immunity-in-vaccinees-with-and-without-prior-exposure-to-flavivirus-infections-or-vaccination-100575777",false,"NCT06776692","Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","Characterisation of Dengue Vaccine (Qdenga®, TAK-003)-Induced Humoral and Cellular Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination","VaQDENV","Inclusion Criteria:\n\n* Subjects of both sexes presenting to the DITM to receive the anti-DENV vaccine whether or not they have had a history of prior DENV or other flaviviruses infection or a history of prior vaccination against other flaviviruses. These data will be recorded in the study CRF.\n* Age \\>= 4 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 4 years.\n* Absence of signed informed consent.",true,"ALL","4 Years",{"count":62,"type":63},402,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the immunity induced by the Qdenga® vaccine in vaccinees.\n\nParticipants that will receive the Dengue vaccine as part of their routine before a travel will be asked to undergo a blood sample at the time of administration of the first dose (T0), 24-48 hours after the first dose (T1) of the vaccine, immediately before the second dose (T2 ) and one to two months after the second dose (T3). Possibly a further sample will be collected within 2 years.",[67],"Dengue Vaccines",[69,70],"Dengue","Vaccine","2025-05-16",{"date":73,"type":74},"2025-05-18","ACTUAL",{"date":76,"type":74},"2024-07-10",{"date":78,"type":63},"2028-01",{"name":5,"class":6},1]